| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ascorbic Acid | 14 | 2012 | 63 | 2.300 |
Why?
|
| Neoplasms | 17 | 2021 | 1033 | 1.840 |
Why?
|
| Vitamins | 8 | 2017 | 91 | 1.010 |
Why?
|
| Stress, Psychological | 6 | 2014 | 541 | 0.950 |
Why?
|
| Micronutrients | 4 | 2015 | 42 | 0.920 |
Why?
|
| Occupational Exposure | 1 | 2023 | 67 | 0.900 |
Why?
|
| Antioxidants | 7 | 2005 | 386 | 0.760 |
Why?
|
| Mutation | 10 | 2016 | 1023 | 0.720 |
Why?
|
| Etoposide | 1 | 2019 | 21 | 0.720 |
Why?
|
| Exosomes | 1 | 2021 | 97 | 0.710 |
Why?
|
| Lipid Peroxidation | 7 | 1998 | 131 | 0.700 |
Why?
|
| Cisplatin | 1 | 2019 | 70 | 0.690 |
Why?
|
| Emergency Medical Services | 1 | 2019 | 55 | 0.690 |
Why?
|
| Enzymes | 3 | 2015 | 30 | 0.690 |
Why?
|
| Charcot-Marie-Tooth Disease | 3 | 2015 | 5 | 0.680 |
Why?
|
| Dietary Supplements | 5 | 2015 | 196 | 0.670 |
Why?
|
| Students | 5 | 2013 | 452 | 0.660 |
Why?
|
| Breast Neoplasms | 9 | 2013 | 1426 | 0.660 |
Why?
|
| Humans | 64 | 2023 | 34853 | 0.650 |
Why?
|
| Malnutrition | 3 | 2015 | 45 | 0.640 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2019 | 107 | 0.640 |
Why?
|
| Feeding Behavior | 5 | 2015 | 418 | 0.630 |
Why?
|
| Adenosine Triphosphatases | 2 | 2016 | 78 | 0.630 |
Why?
|
| Models, Biological | 6 | 2015 | 642 | 0.570 |
Why?
|
| Software | 3 | 2019 | 204 | 0.570 |
Why?
|
| Metabolic Diseases | 1 | 2015 | 32 | 0.510 |
Why?
|
| Cell Cycle Proteins | 2 | 2014 | 220 | 0.480 |
Why?
|
| Stress, Physiological | 1 | 2014 | 137 | 0.460 |
Why?
|
| Energy Metabolism | 2 | 2015 | 160 | 0.430 |
Why?
|
| Diet | 3 | 2014 | 747 | 0.420 |
Why?
|
| Genomics | 1 | 2013 | 201 | 0.410 |
Why?
|
| Minerals | 3 | 2015 | 45 | 0.410 |
Why?
|
| Fish Oils | 4 | 1995 | 12 | 0.390 |
Why?
|
| Dietary Fats | 5 | 1998 | 115 | 0.380 |
Why?
|
| Spastic Paraplegia, Hereditary | 3 | 2016 | 7 | 0.380 |
Why?
|
| Female | 31 | 2019 | 19873 | 0.360 |
Why?
|
| DNA Replication | 3 | 2005 | 148 | 0.360 |
Why?
|
| Industry | 1 | 2009 | 19 | 0.350 |
Why?
|
| Middle Aged | 17 | 2019 | 9642 | 0.350 |
Why?
|
| Alcohol Drinking | 1 | 2013 | 490 | 0.340 |
Why?
|
| Male | 25 | 2021 | 18870 | 0.330 |
Why?
|
| Phenotype | 6 | 2016 | 650 | 0.330 |
Why?
|
| Adult | 19 | 2019 | 11034 | 0.320 |
Why?
|
| Environmental Exposure | 2 | 2023 | 207 | 0.320 |
Why?
|
| Obesity | 5 | 2021 | 965 | 0.320 |
Why?
|
| Pedigree | 7 | 2014 | 64 | 0.310 |
Why?
|
| Nanostructures | 1 | 2009 | 133 | 0.300 |
Why?
|
| Fatty Acids | 3 | 2004 | 118 | 0.300 |
Why?
|
| Genetic Association Studies | 3 | 2016 | 102 | 0.300 |
Why?
|
| Aged | 12 | 2019 | 6448 | 0.300 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2015 | 592 | 0.290 |
Why?
|
| Smoking | 1 | 2013 | 903 | 0.290 |
Why?
|
| Cell Line, Tumor | 4 | 2016 | 2128 | 0.270 |
Why?
|
| Adipose Tissue | 2 | 2021 | 167 | 0.270 |
Why?
|
| Treatment Outcome | 5 | 2019 | 1349 | 0.270 |
Why?
|
| Blood Glucose | 3 | 2015 | 333 | 0.270 |
Why?
|
| Young Adult | 10 | 2019 | 4012 | 0.270 |
Why?
|
| Sepsis | 2 | 2019 | 76 | 0.260 |
Why?
|
| Genetic Variation | 3 | 2016 | 328 | 0.260 |
Why?
|
| Anti-Obesity Agents | 1 | 2004 | 7 | 0.250 |
Why?
|
| Research | 1 | 2006 | 159 | 0.250 |
Why?
|
| Erythrocyte Membrane | 1 | 2004 | 20 | 0.250 |
Why?
|
| Models, Theoretical | 1 | 2006 | 210 | 0.250 |
Why?
|
| Membrane Lipids | 1 | 2004 | 31 | 0.250 |
Why?
|
| Triglycerides | 1 | 2004 | 129 | 0.240 |
Why?
|
| Self Medication | 2 | 2013 | 13 | 0.230 |
Why?
|
| Cell Cycle | 1 | 2004 | 309 | 0.230 |
Why?
|
| Cholesterol | 1 | 2004 | 194 | 0.230 |
Why?
|
| Animals | 17 | 2021 | 14307 | 0.230 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 1995 | 70 | 0.230 |
Why?
|
| Orthomolecular Therapy | 1 | 2002 | 3 | 0.220 |
Why?
|
| Copper Sulfate | 1 | 2002 | 5 | 0.220 |
Why?
|
| Neoplasm Proteins | 1 | 2003 | 203 | 0.210 |
Why?
|
| Puerto Rico | 7 | 2013 | 1352 | 0.210 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 287 | 0.210 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 522 | 0.200 |
Why?
|
| Regenerative Medicine | 1 | 2021 | 11 | 0.200 |
Why?
|
| Antineoplastic Agents | 4 | 2016 | 756 | 0.200 |
Why?
|
| Endoribonucleases | 1 | 2021 | 23 | 0.200 |
Why?
|
| Helminth Proteins | 1 | 2021 | 24 | 0.190 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2000 | 26 | 0.190 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2016 | 107 | 0.190 |
Why?
|
| Risk Assessment | 1 | 2023 | 727 | 0.190 |
Why?
|
| Glycoproteins | 1 | 2021 | 100 | 0.190 |
Why?
|
| Neuromuscular Diseases | 1 | 2000 | 5 | 0.190 |
Why?
|
| Complementary Therapies | 1 | 2000 | 45 | 0.190 |
Why?
|
| Child Nutrition Disorders | 1 | 2000 | 9 | 0.190 |
Why?
|
| Universities | 5 | 2013 | 363 | 0.190 |
Why?
|
| Risk Factors | 5 | 2023 | 3414 | 0.180 |
Why?
|
| Education, Medical | 1 | 2000 | 97 | 0.180 |
Why?
|
| Neutropenia | 1 | 2019 | 18 | 0.180 |
Why?
|
| Eating | 1 | 2021 | 152 | 0.180 |
Why?
|
| Socioeconomic Factors | 5 | 2013 | 1003 | 0.170 |
Why?
|
| Drug Delivery Systems | 1 | 2021 | 182 | 0.170 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 8 | 0.170 |
Why?
|
| Acute Disease | 1 | 2019 | 141 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2006 | 984 | 0.170 |
Why?
|
| Fever | 1 | 2019 | 57 | 0.170 |
Why?
|
| Nutritional Status | 1 | 2000 | 114 | 0.170 |
Why?
|
| United States | 3 | 2023 | 3894 | 0.170 |
Why?
|
| Motor Neuron Disease | 2 | 2015 | 4 | 0.170 |
Why?
|
| Coenzymes | 2 | 2015 | 11 | 0.170 |
Why?
|
| Survival Rate | 1 | 2019 | 310 | 0.170 |
Why?
|
| Computational Biology | 3 | 2019 | 275 | 0.160 |
Why?
|
| Prospective Studies | 2 | 2019 | 1353 | 0.160 |
Why?
|
| Income | 3 | 2013 | 135 | 0.160 |
Why?
|
| Retrospective Studies | 3 | 2019 | 1961 | 0.160 |
Why?
|
| Neural Tube Defects | 1 | 1997 | 3 | 0.160 |
Why?
|
| Folic Acid Deficiency | 1 | 1997 | 6 | 0.160 |
Why?
|
| Alzheimer Disease | 2 | 2016 | 881 | 0.160 |
Why?
|
| Prognosis | 3 | 2005 | 707 | 0.160 |
Why?
|
| Folic Acid | 1 | 1997 | 46 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 178 | 0.160 |
Why?
|
| Vitamin A Deficiency | 1 | 2017 | 14 | 0.150 |
Why?
|
| Macrophages | 2 | 2021 | 431 | 0.150 |
Why?
|
| Schistosomiasis mansoni | 1 | 2017 | 11 | 0.150 |
Why?
|
| Drinking Behavior | 2 | 2015 | 16 | 0.150 |
Why?
|
| Granuloma | 1 | 2017 | 23 | 0.150 |
Why?
|
| Pregnancy | 2 | 2019 | 1503 | 0.150 |
Why?
|
| Food | 2 | 2015 | 95 | 0.150 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2016 | 2 | 0.150 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 254 | 0.150 |
Why?
|
| Receptors, sigma | 1 | 2016 | 16 | 0.150 |
Why?
|
| Cell Membrane | 2 | 2012 | 360 | 0.150 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 964 | 0.150 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 2333 | 0.140 |
Why?
|
| Pilot Projects | 4 | 2015 | 628 | 0.140 |
Why?
|
| Motor Neurons | 2 | 2015 | 72 | 0.140 |
Why?
|
| Adolescent | 5 | 2019 | 5035 | 0.140 |
Why?
|
| Metalloendopeptidases | 1 | 2016 | 15 | 0.140 |
Why?
|
| Adaptation, Psychological | 3 | 2013 | 358 | 0.140 |
Why?
|
| Pregnancy Complications | 1 | 1997 | 132 | 0.140 |
Why?
|
| Mutation, Missense | 1 | 2016 | 80 | 0.140 |
Why?
|
| Thiazoles | 1 | 2016 | 71 | 0.140 |
Why?
|
| Membrane Proteins | 2 | 2016 | 486 | 0.140 |
Why?
|
| Cytoplasmic Dyneins | 1 | 2015 | 2 | 0.140 |
Why?
|
| Mice | 10 | 2021 | 5668 | 0.130 |
Why?
|
| Hazardous Substances | 1 | 2015 | 18 | 0.130 |
Why?
|
| Lipolysis | 1 | 1995 | 18 | 0.130 |
Why?
|
| Carcinogens, Environmental | 1 | 2015 | 34 | 0.130 |
Why?
|
| Glycine-tRNA Ligase | 1 | 2014 | 2 | 0.130 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1996 | 166 | 0.130 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 180 | 0.130 |
Why?
|
| DNA Mutational Analysis | 3 | 2015 | 89 | 0.130 |
Why?
|
| Primary Prevention | 1 | 2015 | 57 | 0.130 |
Why?
|
| Models, Chemical | 1 | 2016 | 201 | 0.130 |
Why?
|
| Optic Atrophy, Autosomal Dominant | 1 | 2014 | 1 | 0.130 |
Why?
|
| Adipocytes | 1 | 1995 | 54 | 0.130 |
Why?
|
| Cell Death | 3 | 2006 | 260 | 0.130 |
Why?
|
| Central Nervous System Stimulants | 2 | 2013 | 165 | 0.130 |
Why?
|
| Liver | 1 | 2017 | 447 | 0.120 |
Why?
|
| GTP Phosphohydrolases | 1 | 2014 | 29 | 0.120 |
Why?
|
| Dietary Fats, Unsaturated | 2 | 1998 | 9 | 0.120 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 66 | 0.120 |
Why?
|
| Bulbar Palsy, Progressive | 1 | 2013 | 1 | 0.120 |
Why?
|
| Presenilin-1 | 1 | 2014 | 27 | 0.120 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2013 | 7 | 0.120 |
Why?
|
| T-Lymphocytes | 1 | 1996 | 341 | 0.120 |
Why?
|
| Genome, Human | 1 | 2014 | 112 | 0.120 |
Why?
|
| Lysosomes | 1 | 2014 | 80 | 0.120 |
Why?
|
| Computer Security | 1 | 2013 | 7 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 207 | 0.120 |
Why?
|
| Caffeine | 1 | 2013 | 26 | 0.120 |
Why?
|
| beta-Glucosidase | 1 | 2013 | 6 | 0.120 |
Why?
|
| Injections, Intravenous | 4 | 2011 | 58 | 0.110 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2013 | 69 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 2 | 2004 | 247 | 0.110 |
Why?
|
| Benzamides | 1 | 2013 | 76 | 0.110 |
Why?
|
| User-Computer Interface | 1 | 2013 | 62 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 2 | 2006 | 480 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 528 | 0.110 |
Why?
|
| Beverages | 1 | 2013 | 64 | 0.110 |
Why?
|
| Fatigue | 1 | 2013 | 79 | 0.110 |
Why?
|
| Dementia | 1 | 2014 | 133 | 0.110 |
Why?
|
| Fermentation | 1 | 2012 | 25 | 0.110 |
Why?
|
| Zebrafish Proteins | 1 | 2013 | 45 | 0.110 |
Why?
|
| Cohort Studies | 4 | 2016 | 1422 | 0.110 |
Why?
|
| Fibroblasts | 1 | 2014 | 252 | 0.110 |
Why?
|
| Glycolysis | 1 | 2012 | 66 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 638 | 0.110 |
Why?
|
| Gene Expression | 3 | 2016 | 639 | 0.110 |
Why?
|
| Diabetic Neuropathies | 1 | 2011 | 11 | 0.100 |
Why?
|
| Cell Division | 3 | 2002 | 296 | 0.100 |
Why?
|
| Internet | 1 | 2013 | 204 | 0.100 |
Why?
|
| Rats | 3 | 2014 | 3261 | 0.100 |
Why?
|
| Cross-Sectional Studies | 3 | 2013 | 2561 | 0.100 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2012 | 342 | 0.100 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 1991 | 30 | 0.100 |
Why?
|
| Oxygen | 1 | 2012 | 193 | 0.100 |
Why?
|
| Infusions, Intravenous | 3 | 2005 | 48 | 0.100 |
Why?
|
| Disease Progression | 3 | 2014 | 580 | 0.100 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 142 | 0.100 |
Why?
|
| Motor Activity | 1 | 2013 | 393 | 0.090 |
Why?
|
| Vitamin E | 1 | 1990 | 56 | 0.090 |
Why?
|
| Cell Proliferation | 2 | 2006 | 1149 | 0.090 |
Why?
|
| Kinetics | 2 | 2014 | 650 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 901 | 0.090 |
Why?
|
| Receptors, Cell Surface | 3 | 2017 | 135 | 0.090 |
Why?
|
| Weight Loss | 2 | 2015 | 124 | 0.090 |
Why?
|
| Inorganic Chemicals | 1 | 2009 | 2 | 0.090 |
Why?
|
| Greenhouse Effect | 1 | 2009 | 5 | 0.090 |
Why?
|
| Schistosoma mansoni | 2 | 2021 | 20 | 0.090 |
Why?
|
| Cell Differentiation | 1 | 2012 | 562 | 0.090 |
Why?
|
| Child | 5 | 2016 | 2875 | 0.090 |
Why?
|
| Nanotubes | 1 | 2009 | 18 | 0.090 |
Why?
|
| Clinical Trials as Topic | 2 | 2013 | 195 | 0.090 |
Why?
|
| Mitochondria | 1 | 2012 | 454 | 0.080 |
Why?
|
| Carbon | 1 | 2009 | 95 | 0.080 |
Why?
|
| Exercise | 1 | 2013 | 524 | 0.080 |
Why?
|
| Nanotechnology | 1 | 2009 | 150 | 0.080 |
Why?
|
| Mice, Nude | 3 | 1993 | 323 | 0.070 |
Why?
|
| Time Factors | 1 | 2010 | 1681 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2016 | 1318 | 0.070 |
Why?
|
| Syndrome | 2 | 2016 | 72 | 0.070 |
Why?
|
| Premenopause | 2 | 2003 | 103 | 0.070 |
Why?
|
| Cell Growth Processes | 1 | 2005 | 41 | 0.070 |
Why?
|
| Forecasting | 1 | 2006 | 124 | 0.070 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2005 | 21 | 0.070 |
Why?
|
| Guinea Pigs | 1 | 2005 | 141 | 0.070 |
Why?
|
| Nutritional Requirements | 2 | 2015 | 37 | 0.060 |
Why?
|
| Gene Amplification | 1 | 2004 | 24 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2004 | 49 | 0.060 |
Why?
|
| Palliative Care | 1 | 2005 | 52 | 0.060 |
Why?
|
| Nanoparticles | 1 | 2009 | 294 | 0.060 |
Why?
|
| Herbal Medicine | 1 | 2004 | 8 | 0.060 |
Why?
|
| Neoplasms, Ductal, Lobular, and Medullary | 1 | 2003 | 1 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 240 | 0.060 |
Why?
|
| Anthropometry | 1 | 2004 | 91 | 0.060 |
Why?
|
| Ki-67 Antigen | 1 | 2003 | 32 | 0.060 |
Why?
|
| Phytotherapy | 1 | 2004 | 62 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2003 | 105 | 0.060 |
Why?
|
| Double-Blind Method | 1 | 2004 | 269 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 298 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2004 | 211 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2005 | 209 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2003 | 269 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2003 | 133 | 0.060 |
Why?
|
| Oxidation-Reduction | 2 | 1995 | 407 | 0.060 |
Why?
|
| Genotype | 2 | 2016 | 641 | 0.050 |
Why?
|
| Neoplasm Transplantation | 2 | 1993 | 114 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 859 | 0.050 |
Why?
|
| Pain | 1 | 2005 | 249 | 0.050 |
Why?
|
| Hypoglycemic Agents | 2 | 2015 | 152 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2014 | 1124 | 0.050 |
Why?
|
| Infant | 2 | 2016 | 1014 | 0.050 |
Why?
|
| Thermogenesis | 1 | 2021 | 20 | 0.050 |
Why?
|
| Holistic Health | 1 | 2000 | 11 | 0.050 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2021 | 41 | 0.050 |
Why?
|
| Pseudobulbar Palsy | 1 | 2000 | 1 | 0.050 |
Why?
|
| Pica | 1 | 2000 | 2 | 0.050 |
Why?
|
| Starvation | 1 | 2000 | 10 | 0.050 |
Why?
|
| Locomotion | 1 | 2021 | 91 | 0.050 |
Why?
|
| Cerebral Palsy | 1 | 2000 | 11 | 0.050 |
Why?
|
| Gastroesophageal Reflux | 1 | 2000 | 29 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 485 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2007 | 794 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2019 | 90 | 0.040 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 1997 | 6 | 0.040 |
Why?
|
| Cebus | 1 | 1997 | 4 | 0.040 |
Why?
|
| Peritoneal Cavity | 1 | 2017 | 6 | 0.040 |
Why?
|
| Mannose-Binding Lectins | 1 | 2017 | 14 | 0.040 |
Why?
|
| Antigens, Differentiation | 1 | 2017 | 24 | 0.040 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2017 | 29 | 0.040 |
Why?
|
| Macrophages, Alveolar | 1 | 2017 | 31 | 0.040 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 35 | 0.040 |
Why?
|
| Interleukin-4 | 1 | 2017 | 69 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1996 | 22 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2021 | 1442 | 0.040 |
Why?
|
| Tretinoin | 1 | 2017 | 50 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1997 | 233 | 0.040 |
Why?
|
| Sequence Analysis | 1 | 2016 | 24 | 0.040 |
Why?
|
| Hungary | 1 | 2016 | 9 | 0.040 |
Why?
|
| HIV | 1 | 1996 | 97 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2016 | 34 | 0.040 |
Why?
|
| Free Radicals | 1 | 1996 | 72 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2016 | 59 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 1530 | 0.040 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2016 | 81 | 0.030 |
Why?
|
| Age of Onset | 1 | 2016 | 98 | 0.030 |
Why?
|
| Anticarcinogenic Agents | 1 | 1996 | 65 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 2016 | 57 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2017 | 392 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2016 | 155 | 0.030 |
Why?
|
| Brain | 2 | 2013 | 1268 | 0.030 |
Why?
|
| Avitaminosis | 1 | 2015 | 2 | 0.030 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 1995 | 34 | 0.030 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2015 | 5 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2016 | 82 | 0.030 |
Why?
|
| Hyperinsulinism | 1 | 2015 | 17 | 0.030 |
Why?
|
| Hela Cells | 1 | 2016 | 344 | 0.030 |
Why?
|
| Autonomic Nervous System | 1 | 2015 | 36 | 0.030 |
Why?
|
| Aminoacylation | 1 | 2014 | 1 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2016 | 197 | 0.030 |
Why?
|
| Yeasts | 1 | 2014 | 19 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2016 | 376 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2015 | 82 | 0.030 |
Why?
|
| Dyslipidemias | 1 | 2015 | 42 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1996 | 214 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 2014 | 106 | 0.030 |
Why?
|
| Magnesium | 1 | 2015 | 95 | 0.030 |
Why?
|
| Germany | 1 | 2014 | 21 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 420 | 0.030 |
Why?
|
| Intracellular Space | 1 | 2014 | 35 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2016 | 467 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2014 | 74 | 0.030 |
Why?
|
| Homozygote | 1 | 2014 | 75 | 0.030 |
Why?
|
| Neuronal Ceroid-Lipofuscinoses | 1 | 2014 | 4 | 0.030 |
Why?
|
| Exons | 1 | 2014 | 80 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2014 | 70 | 0.030 |
Why?
|
| Heterozygote | 1 | 2014 | 91 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2014 | 38 | 0.030 |
Why?
|
| Carnitine | 1 | 2013 | 8 | 0.030 |
Why?
|
| Sarcoma | 1 | 1994 | 9 | 0.030 |
Why?
|
| Sural Nerve | 1 | 2013 | 4 | 0.030 |
Why?
|
| Body Composition | 1 | 1995 | 146 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2013 | 31 | 0.030 |
Why?
|
| Thiobarbiturates | 1 | 1993 | 4 | 0.030 |
Why?
|
| Riboflavin | 1 | 2013 | 24 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2013 | 61 | 0.030 |
Why?
|
| Protein Transport | 1 | 2014 | 286 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2015 | 316 | 0.030 |
Why?
|
| Cacao | 1 | 2013 | 10 | 0.030 |
Why?
|
| Lipids | 1 | 2015 | 222 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2014 | 149 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2013 | 29 | 0.030 |
Why?
|
| Carbonated Beverages | 1 | 2013 | 21 | 0.030 |
Why?
|
| Hypnotics and Sedatives | 1 | 2013 | 27 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 211 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 1995 | 213 | 0.030 |
Why?
|
| Coffee | 1 | 2013 | 20 | 0.030 |
Why?
|
| Proteins | 1 | 2016 | 352 | 0.030 |
Why?
|
| Glucosylceramidase | 1 | 2013 | 7 | 0.030 |
Why?
|
| Prescription Drugs | 1 | 2013 | 31 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2015 | 257 | 0.030 |
Why?
|
| Tea | 1 | 2013 | 41 | 0.030 |
Why?
|
| Corn Oil | 1 | 1992 | 1 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2013 | 53 | 0.030 |
Why?
|
| Butylated Hydroxytoluene | 1 | 1992 | 2 | 0.030 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 1 | 1992 | 15 | 0.030 |
Why?
|
| Hydroquinones | 1 | 1992 | 8 | 0.030 |
Why?
|
| Food Preservation | 1 | 1992 | 5 | 0.030 |
Why?
|
| Carcinoma | 1 | 1994 | 94 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 818 | 0.030 |
Why?
|
| Peroxides | 1 | 1992 | 20 | 0.030 |
Why?
|
| Adenoma | 1 | 1994 | 89 | 0.030 |
Why?
|
| Comorbidity | 1 | 2015 | 606 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 164 | 0.030 |
Why?
|
| DNA Damage | 1 | 2015 | 341 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 1992 | 36 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 271 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 608 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 455 | 0.030 |
Why?
|
| Zebrafish | 1 | 2013 | 118 | 0.030 |
Why?
|
| RNA | 1 | 2013 | 234 | 0.030 |
Why?
|
| Research Design | 1 | 2013 | 292 | 0.030 |
Why?
|
| Family | 1 | 2013 | 162 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2014 | 347 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 1991 | 87 | 0.030 |
Why?
|
| Ascorbic Acid Deficiency | 1 | 2011 | 2 | 0.030 |
Why?
|
| Endothelium | 1 | 2011 | 31 | 0.020 |
Why?
|
| Ferric Compounds | 1 | 1991 | 49 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 1992 | 649 | 0.020 |
Why?
|
| Immunity | 1 | 2011 | 51 | 0.020 |
Why?
|
| Metformin | 1 | 2011 | 64 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 187 | 0.020 |
Why?
|
| Cell Movement | 1 | 2014 | 545 | 0.020 |
Why?
|
| Biological Transport, Active | 1 | 1990 | 25 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 468 | 0.020 |
Why?
|
| Weight Gain | 1 | 1991 | 128 | 0.020 |
Why?
|
| Receptors, LDL | 1 | 1990 | 30 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 1990 | 61 | 0.020 |
Why?
|
| Biological Availability | 1 | 2008 | 84 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 2 | 1998 | 111 | 0.020 |
Why?
|
| Postmenopause | 2 | 1998 | 125 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2008 | 212 | 0.020 |
Why?
|
| Half-Life | 1 | 2007 | 52 | 0.020 |
Why?
|
| Neurons | 1 | 2014 | 1130 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2007 | 91 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 145 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 1998 | 1056 | 0.020 |
Why?
|
| Age Factors | 2 | 1998 | 1007 | 0.020 |
Why?
|
| Terminal Care | 1 | 2005 | 47 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2003 | 34 | 0.010 |
Why?
|
| Virus Diseases | 1 | 2003 | 21 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 2003 | 44 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2003 | 62 | 0.010 |
Why?
|
| HIV Infections | 1 | 1996 | 2207 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 2003 | 74 | 0.010 |
Why?
|
| Menarche | 1 | 1998 | 13 | 0.010 |
Why?
|
| Prostaglandins | 1 | 1998 | 25 | 0.010 |
Why?
|
| Energy Intake | 1 | 1998 | 160 | 0.010 |
Why?
|